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Abstract
Introduction: New onset post transplant diabetes 
mellitus (PTDM) is a common complication of kidney 
transplantation with a negative impact on patient and 
graft survival. Non-white ethnicity is a well known risk 
factor for PTDM. 
Methods: This is a retrospective study of 221 Sudanese 
patients who received live donor kidney transplantation 
in Ahmed Gasim kidney transplant center between 
December 2001 and December 2007, focusing on the 
incidence, clinical course and prognosis of PTDM 
during the first post transplant year, and relating this to 
calcineurin inhibitor use. 
Results: The 12 months cumulative incidence of PTDM 
in our transplant population was 17.6% and all cases 
required treatment with insulin. 53.8% of PTDM cases 
were transient with a median duration of 76 days; by 
12 months post transplant only 6.2% of patients were 
receiving insulin. The 12 months cumulative incidence 
of PTDM was higher in the tacrolimus compared to 
cyclosporine groups (25.4% versus 6.6%; OR 4.8, 95% 
CI: 1.9-12.1; P=0.00). During the follow up period 57.6% 
of PTDM patients in the tacrolimus group were able to 
discontinue insulin compared to 33.3% of PTDM patients 
in the cyclosporine groups (OR 2.7, 95% CI: 0.4-17; 
P=0.3). By 12 months post transplant, the proportion of 
patients receiving insulin was not significantly different 
between the two groups (8.0% versus 4.0%; OR 2.1, 95% 
CI 0.5-8.4; P = 0.2). 
Conclusion: The incidence of PTDM in our transplant 
population is not different from that reported in published 
randomized controlled trials and similarly, in the majority 
of cases PTDM was transient. 
Key words: Post transplant diabetes mellitus, kidney 
transplantation, tacrolimus, cyclosporine, calcineurin 
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Introduction
The development of diabetes mellitus after kidney 
transplantation was first described in 1964 by Starzl, 
who called it ‘steroid diabetes’; Now, post transplant 
diabetes mellitus (PTDM) is recognized as being 
a common complication of kidney transplantation. 
[1,2] The best method for determining the cumulative 
incidence of PTDM associated with the use of different 
immunosuppressive agents is from randomized 
controlled trials, but the results from these trials have 
been quite variable; 74% of this variability is explained 
by the type of immunosuppressive regimen. [1] The 
reported 12 months cumulative incidence of PTDM is 
2-13.3% in patients receiving cyclosporine, azathioprine 
and prednisolone; 11.6 - 25.4% in patients receiving 
tacrolimus, azathioprine and prednisolone; and 4.7-12.2% 
in patients receiving tacrolimus, mycophenolate mofetil 
and prednisolone. [1]
A number of large studies compared the cumulative 
incidence of PTDM in tacrolimus and cyclosporine 
treated patients, and showed that tacrolimus was 
associated with a higher relative risk of PTDM when 
compared to cyclosporine. [3,4] Large studies have also 
shown that PTDM is associated with a higher risk of 
patient mortality and graft loss, even when graft loss was 
censored for patient death. [1,3] Nevertheless, tacrolimus 
is associated with improved graft and patient survival, 
and with a significantly reduced risk of acute rejection 
and steroid resistant acute rejection. [3-5]
Besides calcineurin inhibitors, a number of risk factors 
for PTDM have been identified, including: non-white 
ethnicity, [1,3,6-8] pulse steroid treatment for acute 
rejection, [1] chronic hepatitis C virus infection (HCV) 
[3], and female gender [1,3].
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marrow suppression. Also, five patients from the 
cyclosporine group were switched from azathioprine to 
mycophenolate mofetil. The tacrolimus and cyclosporine 
groups were largely similar, but the tacrolimus group 
contained more paediatric patients (14.7% versus 4.6%, 
P=0.01) (table 1).
PTDM was diagnosed in 39 patients, with an overall 12 
month cumulative incidence of 17.6%. The median time 
for diagnosis was 45 days post transplant, with 67.6% 
of cases being diagnosed within the first three months, 
and 94.6% of cases being diagnosed within the first six 
months.  No cases of PTDM were diagnosed more than 7 
months post transplant. 
The overall prevalence of PTDM was 5.5% (12/219) 
at one month post transplant, 11.7% (24/206) at three 
months post transplant, 11.6% (22/190) at six months 
post transplant, and 6.2% (10/162) at 12 months post 
transplant. 
Overall, PTDM resolved in 21 of 39 patients during the 
follow up period (53.8%). However, in 27 patients with 
PTDM who were followed up for 12 months or more, the 
resolution rate was 66.7%. Transient PTDM had a median 
duration of 76 days (range: 16-270 days), it persisted for 
less than 3 months in 66.7% of cases and for less than 
6 months in 90.5% of cases. Transient PTDM tended to 
occur later than persistent PTDM, with a median time of 
onset of 90 days versus 33 days post transplant. 
All PTDM patients were treated by regular insulin, and 
16% had at least one episode of diabetic ketoacidosis. 
PTDM patients needed re-hospitalization during the 
first post transplant year more often than did patients 
without PTDM (96.4% versus 43.8%, P=0.00), mainly 
for diabetes control or the treatment of infections.
The 12 months cumulative incidence of PTDM was 
higher for the tacrolimus compared to the cyclosporine 
groups (25.4% versus 6.6%; OR 4.8, 95% CI: 1.9-12.1; 
P=0.00). PTDM tended to occur earlier in the tacrolimus 
group, with a median time of onset of 39 days post 
transplant compared to 75 days in the cyclosporine group 
(figure 1). 
During the follow up period, the diabetic status was 
reversed in 57.6% of PTDM patients in the tacrolimus 
group compared to 33.3% of PTDM patients in the 
cyclosporine group (OR 2.7, 95% CI: 0.4-17; P=0.3) 
(figure 2). Among patients who had been follow up for 
12 months or more, the diabetic status was reversed 
in 72.7 (16/22) of PTDM patients in the tacrolimus 
group compared to 40% (2/5) of PTDM patients in the 
cyclosporine group (OR 4, 95% CI: 0.5-30.2; P=0.2).
The prevalence of PTDM was significantly higher in 
the tacrolimus compared to the cyclosporine group at 
one month post transplant (8.5%  versus 1.1%; OR 8.1, 
95% CI: 1-64.2; P=0.02), at three months post transplant 
(16.3% versus 4.8%; OR 3.8, 95% CI: 1.3-11.7; P=0.01), 
and at six months post transplant (15.5% versus 6.3%; 
OR 2.7, 95% CI: 1-7.8; P=0.04). At 12 months post 
transplant, the difference in the prevalence of PTDM 
between the two groups was less marked and did not 
reach statistical significance (8.0% versus 4.0%; OR 2.1, 
95% CI 0.5-8.4; P = 0.2) (figure 3). 
The PTDM and non-PTDM groups were compared for 
a number of possible risk factors. The only identified 
Figure 1: Cumulative incidence of PTDM in the tacrolimus 
and cyclosporine groups
Figure 2: Resolution rate of PTDM in the tacrolimus and 
cyclosporine groups
Some argue that it would be advisable to avoid the use 
of tacrolimus in patients who are already at high risk of 
PTDM because of non-modifiable risk factors, such as 
non-white ethnicity. However, those are the patients who 
are most likely to benefit from tacrolimus, because this 
is one of the factors known to impose a higher risk of 
graft loss.
Here we present a study of the incidence, clinical 
correlates and outcome of PTDM in a group of Sudanese 
patients, relating this to calcineurin inhibitor use. We 
hope to provide an insight into the best management of 
this common complication.
Patients and Methods
This is a retrospective study of a group of Sudanese 
patients who received  living donor kidney transplantation 
at Ahmed Gasim kidney transplant center, Khartoum, 
Sudan, in the period from December 2000 to December 
2007. Only patients who were diabetic before the 
transplant and patients who had primary graft non 
function were excluded from the analysis.
All patients received intravenous methyl prednisolone 
500 mg during the transplant surgery before removal of 
the vascular clamp, followed by a three drug regimen 
composed of cyclosporine (initial dose: 6-8 mg/kg/day, 
target trough level: 200–300 ng/ml reduced gradually 
to 100–150 ng/ml after 6 months) or tacrolimus (initial 
dose: 0.2–0.3 mg/kg/d, target trough level: 15–20 ng/ml 
reduced gradually to 5-7 ng/ml after 6 months) in addition 
to azathioprine (1.5–2 mg/kg/d) and prednisolone (20-30 
mg/d, reduced gradually to 5–7.5 mg/d after 3 months). 
Prior to February 2004, all patients were maintained 
on cyclosporine; as from February 2004, tacrolimus 
became the calcineurin inhibitor of choice. All patients 
received oral trimethoprim–sulphamethoxazole for the 
first 6 months after transplantation. Clinically diagnosed 
and/or biopsy proven acute rejection was treated with 
methylprednisolone 500 mg daily for 3 days.
Data were collected by medical records review from the 
time of transplant until the end of the first post transplant 
year, the end of December 2007, death, or graft failure. 
Patients were divided into two groups according to the 
calcineurin inhibitor they used and examined for the 
presence or absence of PTDM and its clinical correlates. 
PTDM was defined as two random blood glucose values 
≥ 200 mg/dl and/or fasting blood glucose values ≥ 126 
mg/dl taken on two separate occasions, in accordance 
with the definition of diabetes mellitus described by the 
WHO [9], and the international consensus guidelines on 
new-onset diabetes after transplantation [10]. Levels were 
confirmed over two weeks period.  All such patients were 
treated with insulin. Resolution of PTDM was defined by 
fasting blood glucose values ≤ 115 mg/dl taken on two 
separate occasions without insulin or oral hypoglycaemic 
agents.
The 12 months cumulative incidence and clinical 
correlates of PTDM were studied and compared for 
the tacrolimus versus cyclosporine groups. PTDM was 
studied for possible association with patients age, gender, 
HCV infection, and the use of pulse steroids therapy 
for clinically diagnosed and/or biopsy proven acute 
rejection. 
SPSS 15 for Windows was used to perform statistical 
analysis. Cross tabulation and the Chi square analysis 
was used to study possible risk factors and to test for 
their statistical significance.  Results were considered 
statistically significant when P < 0.05.
Results
The study included 221 kidney transplant recipients, 
the great majority (95.5%) received the kidneys from 
live related donors, and 10 patients (4.5%) received the 
kidneys from  live un-related donors. The mean age of 
patients was 35±12 years (range: 8–65 years), including 
23 children (10.4%) aged 18 years or less and the majority 
were males (76.5%),  Thirteen  patients (5.9%) had 
chronic HCV infection. The median duration of follow 
up was 29 months and 73.3% of patients had a minimum 
follow up of 12 months. 
Ninety-one patients were maintained on cyclosporine 
while 130 patients were maintained on tacrolimus, three 
of whom were subsequently switched to cyclosporine 
during the first post transplant year because of suspected 
nephrotoxicity, gastrointestinal intolerance or bone 
Table 1: Characteristics of patients in the tacrolimus and cyclosporine groups
Characteristic tacrolimus (N = 130) cyclosporine (N = 91) P value
Age at transplant (mean ± SD) 34 ± 13 years 36 ± 11 years 0.2
Pediatric patients 14.7 % 4.6 % 0.01
Males 73.8 % 80.2 % 0.2
Chronic HCV infection 4.2 % 10.4 % 0.08
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marrow suppression. Also, five patients from the 
cyclosporine group were switched from azathioprine to 
mycophenolate mofetil. The tacrolimus and cyclosporine 
groups were largely similar, but the tacrolimus group 
contained more paediatric patients (14.7% versus 4.6%, 
P=0.01) (table 1).
PTDM was diagnosed in 39 patients, with an overall 12 
month cumulative incidence of 17.6%. The median time 
for diagnosis was 45 days post transplant, with 67.6% 
of cases being diagnosed within the first three months, 
and 94.6% of cases being diagnosed within the first six 
months.  No cases of PTDM were diagnosed more than 7 
months post transplant. 
The overall prevalence of PTDM was 5.5% (12/219) 
at one month post transplant, 11.7% (24/206) at three 
months post transplant, 11.6% (22/190) at six months 
post transplant, and 6.2% (10/162) at 12 months post 
transplant. 
Overall, PTDM resolved in 21 of 39 patients during the 
follow up period (53.8%). However, in 27 patients with 
PTDM who were followed up for 12 months or more, the 
resolution rate was 66.7%. Transient PTDM had a median 
duration of 76 days (range: 16-270 days), it persisted for 
less than 3 months in 66.7% of cases and for less than 
6 months in 90.5% of cases. Transient PTDM tended to 
occur later than persistent PTDM, with a median time of 
onset of 90 days versus 33 days post transplant. 
All PTDM patients were treated by regular insulin, and 
16% had at least one episode of diabetic ketoacidosis. 
PTDM patients needed re-hospitalization during the 
first post transplant year more often than did patients 
without PTDM (96.4% versus 43.8%, P=0.00), mainly 
for diabetes control or the treatment of infections.
The 12 months cumulative incidence of PTDM was 
higher for the tacrolimus compared to the cyclosporine 
groups (25.4% versus 6.6%; OR 4.8, 95% CI: 1.9-12.1; 
P=0.00). PTDM tended to occur earlier in the tacrolimus 
group, with a median time of onset of 39 days post 
transplant compared to 75 days in the cyclosporine group 
(figure 1). 
During the follow up period, the diabetic status was 
reversed in 57.6% of PTDM patients in the tacrolimus 
group compared to 33.3% of PTDM patients in the 
cyclosporine group (OR 2.7, 95% CI: 0.4-17; P=0.3) 
(figure 2). Among patients who had been follow up for 
12 months or more, the diabetic status was reversed 
in 72.7 (16/22) of PTDM patients in the tacrolimus 
group compared to 40% (2/5) of PTDM patients in the 
cyclosporine group (OR 4, 95% CI: 0.5-30.2; P=0.2).
The prevalence of PTDM was significantly higher in 
the tacrolimus compared to the cyclosporine group at 
one month post transplant (8.5%  versus 1.1%; OR 8.1, 
95% CI: 1-64.2; P=0.02), at three months post transplant 
(16.3% versus 4.8%; OR 3.8, 95% CI: 1.3-11.7; P=0.01), 
and at six months post transplant (15.5% versus 6.3%; 
OR 2.7, 95% CI: 1-7.8; P=0.04). At 12 months post 
transplant, the difference in the prevalence of PTDM 
between the two groups was less marked and did not 
reach statistical significance (8.0% versus 4.0%; OR 2.1, 
95% CI 0.5-8.4; P = 0.2) (figure 3). 
The PTDM and non-PTDM groups were compared for 
a number of possible risk factors. The only identified 
Figure 1: Cumulative incidence of PTDM in the tacrolimus 
and cyclosporine groups
Figure 2: Resolution rate of PTDM in the tacrolimus and 
cyclosporine groups
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non-white ethnicity. However, those are the patients who 
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is one of the factors known to impose a higher risk of 
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patients, relating this to calcineurin inhibitor use. We 
hope to provide an insight into the best management of 
this common complication.
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This is a retrospective study of a group of Sudanese 
patients who received  living donor kidney transplantation 
at Ahmed Gasim kidney transplant center, Khartoum, 
Sudan, in the period from December 2000 to December 
2007. Only patients who were diabetic before the 
transplant and patients who had primary graft non 
function were excluded from the analysis.
All patients received intravenous methyl prednisolone 
500 mg during the transplant surgery before removal of 
the vascular clamp, followed by a three drug regimen 
composed of cyclosporine (initial dose: 6-8 mg/kg/day, 
target trough level: 200–300 ng/ml reduced gradually 
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dose: 0.2–0.3 mg/kg/d, target trough level: 15–20 ng/ml 
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and/or biopsy proven acute rejection was treated with 
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time of transplant until the end of the first post transplant 
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Patients were divided into two groups according to the 
calcineurin inhibitor they used and examined for the 
presence or absence of PTDM and its clinical correlates. 
PTDM was defined as two random blood glucose values 
≥ 200 mg/dl and/or fasting blood glucose values ≥ 126 
mg/dl taken on two separate occasions, in accordance 
with the definition of diabetes mellitus described by the 
WHO [9], and the international consensus guidelines on 
new-onset diabetes after transplantation [10]. Levels were 
confirmed over two weeks period.  All such patients were 
treated with insulin. Resolution of PTDM was defined by 
fasting blood glucose values ≤ 115 mg/dl taken on two 
separate occasions without insulin or oral hypoglycaemic 
agents.
The 12 months cumulative incidence and clinical 
correlates of PTDM were studied and compared for 
the tacrolimus versus cyclosporine groups. PTDM was 
studied for possible association with patients age, gender, 
HCV infection, and the use of pulse steroids therapy 
for clinically diagnosed and/or biopsy proven acute 
rejection. 
SPSS 15 for Windows was used to perform statistical 
analysis. Cross tabulation and the Chi square analysis 
was used to study possible risk factors and to test for 
their statistical significance.  Results were considered 
statistically significant when P < 0.05.
Results
The study included 221 kidney transplant recipients, 
the great majority (95.5%) received the kidneys from 
live related donors, and 10 patients (4.5%) received the 
kidneys from  live un-related donors. The mean age of 
patients was 35±12 years (range: 8–65 years), including 
23 children (10.4%) aged 18 years or less and the majority 
were males (76.5%),  Thirteen  patients (5.9%) had 
chronic HCV infection. The median duration of follow 
up was 29 months and 73.3% of patients had a minimum 
follow up of 12 months. 
Ninety-one patients were maintained on cyclosporine 
while 130 patients were maintained on tacrolimus, three 
of whom were subsequently switched to cyclosporine 
during the first post transplant year because of suspected 
nephrotoxicity, gastrointestinal intolerance or bone 
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discontinued insulin within the first year. [15] Also, in 
the European multicentre study, 2.2% of cyclosporine 
treated patients developed insulin dependent PTDM, and 
the same proportion (2.2%) continued to receive insulin 
at 12 months. [16] 
The use of tacrolimus and female gender were the only 
statistically significant risk factor for PTDM in our patient 
group, although chronic HCV infection and the need for 
at least one course of pulse steroid treatment for acute 
rejection during the first post transplant year had a clear 
tendency to be associated with PTDM.  The incidence of 
PTDM increased significantly with the number of pulse 
steroid courses used during the first post transplant year.
All our cases of transient PTDM experienced resolution 
of their diabetes within 12 months of transplant, this 
concurs with Kiberd et al, who found that resolution 
occurred within six months for 94% of his patients. [17] 
If PTDM persists up to 12 months post transplant, it is 
unlikely to resolve; and switching to cyclosporine may 
be a valid therapeutic option; the reported success rate of 
this approach is (44-65%). [18-20]
The choice of calcineurin inhibitor on the bases of 
diabetogenic risk should not be made at the expense 
of efficacy; measures such as steroid minimization or 
withdrawal and lower tacrolimus exposure may help 
maintain better long term survival. 
Conclusion
The incidence of PTDM in our transplant population is 
no different from that reported in published randomized 
controlled trials, and a considerable proportion of cases 
are transient. The  resolution rate among our patients was 
remarkable. The transient nature of most PTDM cases in 
our population mandates an individualized approach for 
management, so as not to deprive our patients from the 
well known benefits of tacrolimus on graft and patient 
survival.
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risk factors for PTDM were the use of tacrolimus versus 
cyclosporine (25.4% versus 6.6%; OR 4.8, 95% CI: 
1.9-12.1; P=0.00) and female gender (26.9% versus 
14.8%; OR 2.1, 95% CI: 1-4.5; P=0.04). Patients with 
chronic HCV infection tended to have a higher incidence 
of PTDM (38.5% versus 16.8%; OR 3.1, 95% CI: 
0.9-10.1; P=0.07) as did patients who received at least 
one course of pulse steroid treatment for acute rejection 
during the first post transplant year (25.9% versus 
15.2%; OR 2, 95% CI: 0.9-4; P=0.06); however, this 
association did not reach statistical significant. Pediatric 
age group was not associated with a higher incidence 
of PTDM (17.4% versus 18.1%; OR 1, 95% CI: 0.3-3; 
P=0.6). The incidence of PTDM among patients who had 
no episodes of acute rejection was 15.2% (25/164), the 
incidence of PTDM among patients who had one, two or 
three episodes of acute rejection within the first year was 
21.3% (10/47), 42.9% (3/7) and 100% (1/1) respectively 
(P = 0.03). 
Discussion
The cumulative incidence of PTDM at 12 months post-
transplant in our transplant population was 17.6%; this is 
comparable to the incidence reported in the literature. A 
considerable proportion of PTDM cases resolved within 
the study period (53.8%), and among patients who had 
been followed up for at least 12 months the resolution 
rate was 66.7%; consequently, the prevalence of PTDM 
at 12 months post transplant was only 6.2%. PTDM was 
associated with significant morbidity, the incidence of 
DKA was rather high (16%), and all patients were treated 
with regular insulin. PTDM patients were much more 
likely to need hospital admission than patients who did 
not develop PTDM, mainly for diabetes control and the 
treatment of infections.
The cumulative incidence of PTDM in the cyclosporine 
group (6.6%) is similar to the estimates reported from 
randomized controlled trials in patients receiving 
cyclosporine, azathioprine and prednisolone (2-13.3%). 
[1] Similarly, the cumulative incidence of PTDM in the 
tacrolimus group (25.4%) was within  the  reported range in 
randomized controlled trials in patients receiving tacrolimus, 
azathioprine and prednisolone (11.6-25.4%). [1]
The cumulative incidence of PTDM in the cyclosporine 
group (6.6%) is much lower than the incidence reported 
in a group of cyclosporine treated patients of Arab origin 
in a Kuwaiti center (29.6%), which was partly attributed 
to the fact that Kuwait has a high background incidence of 
obesity and Type II diabetes mellitus [11]; the incidence 
was also lower than the incidence reported from a group 
of cyclosporine treated Saudi patients (41.4%). [12]
The cumulative incidence of PTDM in the tacrolimus 
group (25.4%) is also lower than the incidence reported 
by Hricik et al in a group of tacrolimus treated African 
American kidney transplant recipients (36%). [13]
In this study, the use of tacrolimus compared with 
cyclosporine was associated with a significantly higher 
risk of PTDM (25.4% versus 6.6%; OR 4.8, 95% CI: 
1.9-12.1; P=0.000). The observed difference is consistent 
with the previous observation that despite the higher risk 
of PTDM attributed to non-white ethnicity, tacrolimus 
was associated with a lower relative risk of PTDM in 
non-white patients (29% versus 7.8%; RR 3.7) than white 
patients (12% versus 1.2%; RR 10.6) when compared 
with cyclosporine. [14]
In this study, 57.6% of tacrolimus treated PTDM patients 
were able to discontinue insulin therapy during the study 
period, and among those who had been followed up for 
12 months 72.7% were able to discontinue insulin therapy 
within the first post transplant year. In the US multicentre 
study, only 23.3% of tacrolimus treated PTDM patients 
discontinued insulin within the first year, and the rate 
of reversal of insulin dependence was only 41.2% by 5 
years. [15] In the European multicentre study, 8.3% of 
tacrolimus treated patients developed insulin dependent 
PTDM, and by 12 months, the proportion of tacrolimus 
treated patients receiving insulin reduced to 5.5%. [16]
In this study, 33.3% of cyclosporine treated PTDM patients 
were able to discontinue insulin therapy during the study 
period, and among those who had been followed up for 
12 months 40% were able to discontinue insulin therapy 
within the first post transplant year. In the US multicentre 
study, only 16.7% of cyclosporine treated PTDM patients 
Figure 3: prevalence of PTDM at different time points post 
transplant
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discontinued insulin within the first year. [15] Also, in 
the European multicentre study, 2.2% of cyclosporine 
treated patients developed insulin dependent PTDM, and 
the same proportion (2.2%) continued to receive insulin 
at 12 months. [16] 
The use of tacrolimus and female gender were the only 
statistically significant risk factor for PTDM in our patient 
group, although chronic HCV infection and the need for 
at least one course of pulse steroid treatment for acute 
rejection during the first post transplant year had a clear 
tendency to be associated with PTDM.  The incidence of 
PTDM increased significantly with the number of pulse 
steroid courses used during the first post transplant year.
All our cases of transient PTDM experienced resolution 
of their diabetes within 12 months of transplant, this 
concurs with Kiberd et al, who found that resolution 
occurred within six months for 94% of his patients. [17] 
If PTDM persists up to 12 months post transplant, it is 
unlikely to resolve; and switching to cyclosporine may 
be a valid therapeutic option; the reported success rate of 
this approach is (44-65%). [18-20]
The choice of calcineurin inhibitor on the bases of 
diabetogenic risk should not be made at the expense 
of efficacy; measures such as steroid minimization or 
withdrawal and lower tacrolimus exposure may help 
maintain better long term survival. 
Conclusion
The incidence of PTDM in our transplant population is 
no different from that reported in published randomized 
controlled trials, and a considerable proportion of cases 
are transient. The  resolution rate among our patients was 
remarkable. The transient nature of most PTDM cases in 
our population mandates an individualized approach for 
management, so as not to deprive our patients from the 
well known benefits of tacrolimus on graft and patient 
survival.
References
1. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, 
Kudva YC. Post transplantation Diabetes: A systematic 
review of the literature. Diabetes Care. 2002;25:583-92.
2. Heisel O, Heisel R, Balshaw R, Keown P. New 
onset diabetes mellitus in patients receiving calcineurin 
inhibitors: a systematic review and meta-analysis. Am J 
Transplant. 2004 Apr;4(4):583-95. 
3. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. 
Diabetes mellitus after kidney transplantation in the 
United States. Am J Transplant. 2003 Feb;3(2):178-85.
4. Webster A, Woodroffe RC, Taylor RS, Chapman 
JR, Craig JC.  Tacrolimus versus cyclosporine as 
primary immunosuppression for kidney transplant 
recipients. Cochrane Database Syst Rev. 2005 Oct 
19;(4):CD003961.
5. Knoll GA, Bell RC. Tacrolimus versus cyclosporin 
for immunosuppression in renal transplantation: 
meta-analysis of randomised trials. BMJ. 1999 Apr 
24;318(7191):1104-7.
6.  Rodrigo E, de Cos MA, Fernández-Fresnedo G, 
Sánchez B, Ruiz JC, Piñera C, Palomar R, Cotorruelo 
JG, Gómez-Alamillo C, de Castro SS, de Francisco AL, 
Arias M.  Higher initial tacrolimus blood levels and 
concentration-dose ratios in kidney transplant recipients 
who develop diabetes mellitus. Transplant Proc. 2005 
Nov;37(9):3819-20. 
7. Dooldeniya MD, Dupont PJ, He X, Johnson RJ, Joshi T, 
Basra R, Johnston A, Warrens AN. Renal transplantation 
in Indo-Asian patients in the UK. Am J Transplant. 2006 
Apr;6(4):761-9.
8. Greenspan LC, Gitelman SE, Leung MA, Glidden 
DV, Mathias RS. Increased incidence in post-transplant 
diabetes mellitus in children: a case-control analysis. 
Pediatr Nephrol. 2002 Jan;17(1):1-5.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and 
classification of diabetes mellitus and its complications. 
Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med. 
1998 Jul;15(7):539-53.
10. Wilkinson A, Davidson J, Dotta F, Home PD, Keown 
P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, 
Naicker S, OConnell P, Schnitzler M, Standl E, Torregosa 
JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing 
M. Guidelines for the treatment and management of 
new-onset diabetes after transplantation. Clin Transplant. 
2005 Jun;19(3):291-8.
11. Johny KV, Nampoory MR, Costandi JN, Gupta RK, 
Ninan VT, Samhan M, Muzairai I, Al-Mousawi M. High 
incidence of post-transplant diabetes mellitus in Kuwait. 
Diabetes Res Clin Pract. 2002 Feb;55(2):123-30.
12. Onwubalili JK, Obineche EN. High incidence of 
post-transplant diabetes mellitus in a single-centre study. 
Nephrol Dial Transplant. 1992;7(4):346-9.
13. Hricik DE, Anton HA, Knauss TC, Rodriguez V, 
Seaman D, Siegel C,Valente J, Schulak JA. Outcomes 
of African American kidney transplant recipients 
treated with sirolimus, tacrolimus, and corticosteroids. 
Transplantation. 2002 Jul 27;74(2):189-93.
risk factors for PTDM were the use of tacrolimus versus 
cyclosporine (25.4% versus 6.6%; OR 4.8, 95% CI: 
1.9-12.1; P=0.00) and female gender (26.9% versus 
14.8%; OR 2.1, 95% CI: 1-4.5; P=0.04). Patients with 
chronic HCV infection tended to have a higher incidence 
of PTDM (38.5% versus 16.8%; OR 3.1, 95% CI: 
0.9-10.1; P=0.07) as did patients who received at least 
one course of pulse steroid treatment for acute rejection 
during the first post transplant year (25.9% versus 
15.2%; OR 2, 95% CI: 0.9-4; P=0.06); however, this 
association did not reach statistical significant. Pediatric 
age group was not associated with a higher incidence 
of PTDM (17.4% versus 18.1%; OR 1, 95% CI: 0.3-3; 
P=0.6). The incidence of PTDM among patients who had 
no episodes of acute rejection was 15.2% (25/164), the 
incidence of PTDM among patients who had one, two or 
three episodes of acute rejection within the first year was 
21.3% (10/47), 42.9% (3/7) and 100% (1/1) respectively 
(P = 0.03). 
Discussion
The cumulative incidence of PTDM at 12 months post-
transplant in our transplant population was 17.6%; this is 
comparable to the incidence reported in the literature. A 
considerable proportion of PTDM cases resolved within 
the study period (53.8%), and among patients who had 
been followed up for at least 12 months the resolution 
rate was 66.7%; consequently, the prevalence of PTDM 
at 12 months post transplant was only 6.2%. PTDM was 
associated with significant morbidity, the incidence of 
DKA was rather high (16%), and all patients were treated 
with regular insulin. PTDM patients were much more 
likely to need hospital admission than patients who did 
not develop PTDM, mainly for diabetes control and the 
treatment of infections.
The cumulative incidence of PTDM in the cyclosporine 
group (6.6%) is similar to the estimates reported from 
randomized controlled trials in patients receiving 
cyclosporine, azathioprine and prednisolone (2-13.3%). 
[1] Similarly, the cumulative incidence of PTDM in the 
tacrolimus group (25.4%) was within  the  reported range in 
randomized controlled trials in patients receiving tacrolimus, 
azathioprine and prednisolone (11.6-25.4%). [1]
The cumulative incidence of PTDM in the cyclosporine 
group (6.6%) is much lower than the incidence reported 
in a group of cyclosporine treated patients of Arab origin 
in a Kuwaiti center (29.6%), which was partly attributed 
to the fact that Kuwait has a high background incidence of 
obesity and Type II diabetes mellitus [11]; the incidence 
was also lower than the incidence reported from a group 
of cyclosporine treated Saudi patients (41.4%). [12]
The cumulative incidence of PTDM in the tacrolimus 
group (25.4%) is also lower than the incidence reported 
by Hricik et al in a group of tacrolimus treated African 
American kidney transplant recipients (36%). [13]
In this study, the use of tacrolimus compared with 
cyclosporine was associated with a significantly higher 
risk of PTDM (25.4% versus 6.6%; OR 4.8, 95% CI: 
1.9-12.1; P=0.000). The observed difference is consistent 
with the previous observation that despite the higher risk 
of PTDM attributed to non-white ethnicity, tacrolimus 
was associated with a lower relative risk of PTDM in 
non-white patients (29% versus 7.8%; RR 3.7) than white 
patients (12% versus 1.2%; RR 10.6) when compared 
with cyclosporine. [14]
In this study, 57.6% of tacrolimus treated PTDM patients 
were able to discontinue insulin therapy during the study 
period, and among those who had been followed up for 
12 months 72.7% were able to discontinue insulin therapy 
within the first post transplant year. In the US multicentre 
study, only 23.3% of tacrolimus treated PTDM patients 
discontinued insulin within the first year, and the rate 
of reversal of insulin dependence was only 41.2% by 5 
years. [15] In the European multicentre study, 8.3% of 
tacrolimus treated patients developed insulin dependent 
PTDM, and by 12 months, the proportion of tacrolimus 
treated patients receiving insulin reduced to 5.5%. [16]
In this study, 33.3% of cyclosporine treated PTDM patients 
were able to discontinue insulin therapy during the study 
period, and among those who had been followed up for 
12 months 40% were able to discontinue insulin therapy 
within the first post transplant year. In the US multicentre 
study, only 16.7% of cyclosporine treated PTDM patients 




14. Cavaille-Coll MW, Elashoff MR. Commentary 
on a comparison of tacrolimus and cyclosporine for 
immunosuppression after cadaveric renal transplantation. 
Transplantation. 1998;65:142–5.
15. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. 
A long-term comparison of tacrolimus (FK506) and 
cyclosporine in kidney transplantation: evidence for 
improved allograft survival at five years. Transplantation. 
2002 Mar 15;73(5):775-82.
16. Mayer AD. Chronic rejection and graft half-life: 
five-year follow-up of the European Tacrolimus Multicenter 
Renal Study. Transplant Proc. 2002 Aug;34(5):1491-2.
17. Kiberd M, Panek R, Kiberd BA. New onset diabetes 
mellitus post-kidney transplantation. Clin Transplant. 
2006 Sep-Oct;20(5):634-9.
18.  Bouchta NB, Ghisdal L, Abramowicz D, Broeders N, 
Surquin M, Hoang AD, Wissing KM. Conversion from 
tacrolimus to cyclosporin is associated with a significant 
improvement of glucose metabolism in patients with 
new-onset diabetes mellitus after renal transplantation. 
Transplant Proc. 2005 May;37(4):1857-60.
19.  Oberholzer J, Thielke J, Hatipoglu B, Testa G, Sankary 
HN, Benedetti E. Immediate conversion from tacrolimus 
to cyclosporine in the treatment of posttransplantation 
diabetes mellitus. Transplant Proc. 2005 Mar;37(2):999-
1000.
20. Wyzgal J, Oldakowska-Jedynak U, Paczek L. Post 
transplantation diabetes mellitus under calcineurin 
inhibitor. Transplant Proc. 2003;35(6):2216-18. 
